1-May-2026
ICON plc Delays Annual 20-F Amid Restatement
TipRanks (Fri, 1-May 6:52 PM ET)
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Icon (ICLR)
TipRanks (Thu, 30-Apr 10:30 PM ET)
ICON rebounds as accounting probe concludes
Seeking Alpha News (Wed, 29-Apr 1:28 PM ET)
TipRanks (Wed, 29-Apr 11:50 AM ET)
Market Chameleon (Wed, 29-Apr 7:47 AM ET)
ICON Audit Committee Finds Revenue Overstatement Below 2%—Restatement Process Nears Conclusion
Market Chameleon (Wed, 29-Apr 3:58 AM ET)
ICON to Restate 2023–2025 Results After Audit Flags Revenue Recognition Issues
TipRanks (Wed, 29-Apr 7:52 AM ET)
Business Wire (Wed, 29-Apr 7:00 AM ET)
ICON and Advarra Introduce New 'Research-Ready,' Connected Site Network Model
Business Wire (Tue, 24-Mar 8:00 AM ET)
Globe Newswire (Mon, 16-Mar 11:02 AM ET)
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
Icon PLC - trades on the NASDAQ stock market under the symbol ICLR.
As of May 1, 2026, ICLR stock price declined to $112.85 with 912,862 million shares trading.
ICLR has a beta of 1.53, meaning it tends to be more sensitive to market movements. ICLR has a correlation of 0.09 to the broad based SPY ETF.
ICLR has a market cap of $8.62 billion. This is considered a Mid Cap stock.
Last quarter Icon PLC - reported $2 billion in Revenue and $3.31 earnings per share. This beat revenue expectation by $62 million and exceeded earnings estimates by $.08.
In the last 3 years, ICLR traded as high as $347.72 and as low as $66.57.
The top ETF exchange traded funds that ICLR belongs to (by Net Assets): PIEQ, DSTL, DFSV, SPDW, DFAT.
ICLR has underperformed the market in the last year with a price return of -22.3% while the SPY ETF gained +30.4%. ICLR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -37.4% and -5.7%, respectively, while the SPY returned +4.4% and +1.5%, respectively.
ICLR support price is $113.89 and resistance is $122.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ICLR shares will trade within this expected range on the day.